Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Express Scripts
Johnson and Johnson
Mallinckrodt
Colorcon

Last Updated: May 28, 2022

ADDERALL XR 20 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Adderall Xr 20, and what generic alternatives are available?

Adderall Xr 20 is a drug marketed by Takeda Pharms Usa and is included in one NDA.

The generic ingredient in ADDERALL XR 20 is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. There are fifty-five drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.

Drug patent expirations by year for ADDERALL XR 20
Recent Clinical Trials for ADDERALL XR 20

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of California, Los AngelesEarly Phase 1
University of WyomingPhase 2
National Institute on Drug Abuse (NIDA)Phase 4

See all ADDERALL XR 20 clinical trials

US Patents and Regulatory Information for ADDERALL XR 20

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa ADDERALL XR 20 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-002 Oct 11, 2001 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ADDERALL XR 20

International Patents for ADDERALL XR 20

See the table below for patents covering ADDERALL XR 20 around the world.

Country Patent Number Title Estimated Expiration
Japan 2008303223 ORAL PULSED DOSE DRUG DELIVERY SYSTEM See Plans and Pricing
European Patent Office 1123087 SYSTEME D'ADMINISTRATION DE MEDICAMENTS PAR DOSES PULSEES PAR VOIE ORALE (ORAL PULSED DOSE DRUG DELIVERY SYSTEM) See Plans and Pricing
European Patent Office 1977736 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Baxter
Dow
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.